This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Mannkind Falls on Talk of Partner, FDA Delay: BioBuzz

VALENCIA, Calif. (TheStreet) -- Mannkind (MNKD) shares plunged Tuesday morning after the company said it was delaying efforts to sign a partner for its inhaled insulin Afresa.

The disclosure is raising fears that the Food and Drug Administration may delay Afresa's approval.

Mannkind disclosed that it would not meet its previously stated goal of signing a partnership for Afrea before the end of the year, according to an 8-K filing with the Securities and Exchange Commission.

"We made substantial progress toward a definitive agreement with a lead potential partner; however, as the discussions progressed, we came to believe that it would be more productive to complete a partnership after we have received a response from the United States Food and Drug Administration, or FDA, regarding our new drug application for Afresa," said Mannkind in its SEC filing.

Speaking at the JMP Securities conference in New York this morning, Mannkind executives were also cautious when asked if they thought FDA would grant full approval to Afresa on or before the agency's approval decision deadline, or PDUFA date, of Jan. 16, 2010.

The risk of the company getting a complete response letter from the FDA is now significantly increased," said JMP analyst Jason Butler, speaking by phone from his firm's conference. "The company said a partner is not willing to sign on before the FDA's PDUFA date."

Mannkind has also not indicated whether it will be asked to bring Afresa in front of an FDA advisory panel prior to the agency's approval decision date.

Mannkind shares are down 23% to $7.01 in recent trading.

No Lupus Confab Invite for Immunomedics

(At 7:42 AM EDT)

Lupus will be a big focus of the upcoming annual meeting of the American College of Rheumatology (ACR) next week, but Immunomedics (IMMU) has been shut out of the discussion.

Immunomedics and its partner UCB submitted a late-breaker abstract seeking to present phase II data on its lupus drug epratuzumab, but ACR didn't accept the submission.

"UCB did file their late-breaking abstract in time. Unfortunately, ACR only accepted 6 late breakers and ours was not chosen," confirmed Immunomedics' investor relations spokesman Chau Cheng, in an email response.

Top-line data from a phase II study of epratuzumab in lupus patients were announced on August 27, sending shares of Immunomedics soaring 61% to $6.84.

Since then, the stock has given back some of those gains, closing Monday at $4.99. Immunomedics owns the rights to epratuzumab but licensed development of the drug in lupus to the Belgian drug firm UCB in 2006.

Human Genome Sciences (HGSI) will be presenting detailed data from its successful phase III study of Benlysta in lupus patients at the ACR meeting on Oct. 20. The full ACR meeting runs Oct. 16-21.

"As management had signaled, the abstract reveals that Benlysta did significantly benefit lupus patients on clinically important flare endpoints, and that the drug's safety profile is indistinguishable from placebo. This data should increase confidence in the quality of the Benlysta dataset and in the likelihood of a positive result in the second phase III study, BLISS-76, to be reported in November," writes Monness Crespi Hardt analyst Avik Roy in a research note published Monday.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,040.55 +1.06 0.01%
S&P 500 1,990.05 -2.32 -0.12%
NASDAQ 4,528.5640 -3.54 -0.08%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs